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The clinical-immunological spectrum of human Leishmania (L.) infantum chagasi infection in Amazonian Brazil was recently
reviewed based on clinical, DTH, and IFAT (IgG) evaluations that identified five profiles: three asymptomatic (asymptomatic
infection, AI; subclinical resistant infection, SRI; and indeterminate initial infection, III) and two symptomatic (symptomatic
infection, SI; American visceral leishmaniasis, AVL; and subclinical oligosymptomatic infection, SOI). TNF-𝛼, IL-4, IL-6, and
IL-10 serum cytokines were analyzed using multiplexed Cytometric Bead Array in 161 samples from endemic areas in the Brazilian
Amazon: SI [AVL] (21 cases), III (49), SRI (19), SOI (12), AI (36), and a control group [CG] (24).The highest IL-6 serum levels were
observed in the SI profile (AVL); higher IL-10 serum levels were observed in SI than in SOI or CG and in AI and III than in SOI;
higher TNF-𝛼 serum levels were seen in SI than in CG. Positive correlations were found between IL-6 and IL-10 serum levels in
the SI and III profiles and between IL-6 and TNF-𝛼 and between IL-4 and TNF-𝛼 in the III profile. These results provide strong
evidence for associating IL-6 and IL-10 with the immunopathogenesis of AVL and help clarify the role of these cytokines in the
infection spectrum.
1. Introduction
Although American visceral leishmaniasis (AVL) is consid-
ered the major clinical feature of Leishmania (L.) infantum
chagasi and human immune response, there is no doubt that
additional clinical-immunological features resulting from
this interaction could also contribute to better understanding
the entire immune response to infection. New findings con-
cerning human L. (L.) i. chagasi infection in Para´ State, Ama-
zonian Brazil, based on the combined use of the semiquanti-
tative delayed-type hypersensitivity (DTH) and indirect fluo-
rescent antibody tests (IFAT-IgG) have confirmed their ability
to diagnose either asymptomatic or symptomatic infections
in endemic areas [1]. The high specificity of this diagnostic
approach using species-specific L. (L.) i. chagasi antigens,
promastigotes for DTH, and amastigotes for IFAT (IgG),
associated with the clinical status of the infected individuals,
has allowed the identification of a wide infection spec-
trum composed of five clinical-immunological profiles: three
asymptomatic, (1) asymptomatic infection (AI) [DTH+/++++,
IFAT−], (2) subclinical resistant infection (SRI) [DTH+/++++,
IFAT+/++], and (3) indeterminate initial infection (III)
[DTH−, IFAT+/++] and two symptomatic, (4) symptomatic
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Figure 1: Dynamics of the clinical and immunological evolution of human L. (L.) i. chagasi infection in the Brazilian Amazon region. IFAT:
indirect fluorescent antibody test (IgG). IFAT++++: 5120–10240 (IgG). IFAT+++: 1280–2560 (IgG). IFAT++: 320–640 (IgG). IFAT+: 80–160 (IgG).
IFAT−: negative reaction. LST: Leishmanin skin test (= DTH). LST++++: exacerbate reaction (≥16mm). LST+++: strong reaction (13–15mm).
LST++: moderate reaction (9–12mm). LST+: weak reaction (5–8mm). LST−: negative reaction. AI: asymptomatic infection. SI: symptomatic
infection (= AVL). SOI: subclinical oligosymptomatic infection. SRI: subclinical resistant infection. III: indeterminate initial infection.
infection (SI) [AVL] and (5) subclinical oligosymptomatic
infection (SOI), both with the same immune profile [DTH−,
IFAT+++/++++].This diagnostic approach confirmed the three
previously established profiles (AI, SI [AVL], and SOI) as well
as two new ones (SRI and III) that represent new infection
stages [2, 3].
While the AI profile is characterized by a positive DTH
reaction and the absence of an IgG-antibody response (below
the IFAT-IgG dilution cut-off of 1 : 80) that are strongly linked
to genetic resistance to infection [4], the SI profile (AVL) is
associated with genetic susceptibility to infection, with strong
inhibition of DTH and high expression of the IgG-antibody
response. The SOI and SRI profiles represent borderline
genetic expressions of susceptibility and resistance, respec-
tively. The former is characterized by mild clinical signs of
susceptibility (such as fever, asthenia, cutaneous pallor, and
moderate enlargement of the spleen) but with spontaneous
clinical resolution of the infection after one- to two-month
period [5], while the latter is characterized by an asymp-
tomatic profile representing an evolved stage towards the
resistant AI profile. The asymptomatic III profile represents
the earliest stage of infection, which is not well defined from
an immune-genetic point of view but has the capacity to
evolve into either a resistant AI profile or a susceptible SI
(AVL) profile.Thus, depending on the genetic background of
the infected individuals, the infection can evolve to a resistant
AI profile or to a susceptible SI profile (AVL), although pass-
ing first through either the SRI or the SOI profile, respectively
(Figure 1). We therefore undertook two prospective studies
in the Brazilian Amazon focusing on the dynamics of the
clinical and immunological evolution of infection and have
estimated that 1–3% of the cases of the III profile will evolve
to classical AVL [6, 7].
The innate immune response of the clinical-immunolog-
ical profiles of human L. (L.) i. chagasi infection has not yet
been exhaustively examined, as most studies have focused on
the immunopathological disorders at the extreme pathogenic
pole of this spectrum, the characteristic Th2-type cell
response-derived SI profile (AVL). An immunopathogenic
role of IL-10 (but not IL-4 or TGF-𝛽) has been observed in
in vitro T-cell suppression assays using cultured-stimulated
peripheral bloodmononuclear cells (PBMC) from curedAVL
patients [8]; Caldas et al. [9] reported similar results for the
plasma levels of IL-10 and IFN-𝛾 from AVL patients, indicat-
ing that IL-10 can suppress the beneficial activity of IFN-𝛾
activation of infected macrophages. We have also observed
higher serum levels of IL-10 than IFN-𝛾 in children with
severe AVL, reinforcing the presumed immunopathogenic
role of IL-10 [10]. IL-6 has recently been implicated, however,
as one of most pathogenic inflammatory cytokines, being
associated with infection severity and complications in chil-
dren who later died from AVL in Piaui State in northeastern
Brazil [11].
In terms of asymptomatic (AI, SRI, and III) and subclin-
ical oligosymptomatic (SOI) infection profiles, a number of
studies have confirmed the beneficial Th1 actions of IFN-𝛾
and IL-12 cytokines in overcoming the Th2-inhibiting effect
of IL-10 in cultured-stimulated PBMC from asymptomatic
individuals with positive DTH reactions [12]. In two other
experiments, following a short-term L. (L.) i. chagasi-sol-
uble leishmania antigen/SLA stimulation of cultured whole
peripheral blood, increased ratios of IFN-𝛾+, TNF-𝛼+, IL-4+,
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and IL-10+ neutrophils and TNF-𝛼+ and IL-10+ monocytes
were observed in asymptomatic individuals, suggesting a
mixed pattern (Th1/Th2) of cytokine production due to innate
immune responses in those individuals [13, 14]. The SOI
profile demonstrated variable serum levels of IL-2 in 52.3% of
the patients, IL-12 in 85.2%, IFN-𝛾 in 48.1%, IL-10 in 88.9%,
and TNF-𝛼 in 100%; IL-4 was not detected, confirming both
Th1 and Th2 cytokine profiles in the subclinical oligosymp-
tomatic form of infection [5]. The role of TNF-𝛼 within
the infection spectrum is not yet fully understood; there is
evidence for moderate plasma levels in asymptomatic indi-
viduals with positive DTH reactions, but high plasma levels
in AVL patients showing negative DTH responses, suggesting
a dubious role for TNF-𝛼 in infection outcomes [15–17].
Taking these observations into account, we present here
our findings concerning TNF-𝛼, IL-4, IL-6, and IL-10 serum
cytokine responses over the entire clinical-immunological
spectrum of human L. (L.) i. chagasi-infection, with emphasis
on the immunopathogenic role of IL-6 and IL-10 which may
aid in preventing or reducing the morbidity of severe AVL.
2. Materials and Methods
2.1. Study Area. The present study was carried out in the
town of Santana do Cafezal, located on the banks of the
Cafezal River, 7 km from the administrative center of the
Municipality of Barcarena (01∘30󸀠S × 48∘37󸀠W), within the
metropolitan region of Bele´m, the capital of Para´ State, in
the Brazilian Amazon.This area is dominated by plantations,
with occasional patches of secondary forest. The climate
and the environmental conditions of the study area were
previously described in more detail [2].
2.2. Study Design and Clinical Samples. This cross-sectional
study used flow cytometry to examine 161 serum samples
from L. (L.) i. chagasi-infected and noninfected individuals
(both genders, and ≥1 year old) from an endemic area of
AVL in Para´ State in the Brazilian Amazon. The individ-
uals showed five clinical-immunological infection profiles:
symptomatic infection (SI) [AVL] (21 cases), indeterminate
initial infection (III) (49 cases), subclinical resistant infec-
tion (SRI) (19), subclinical oligosymptomatic infection (SOI)
(12), and asymptomatic infection (AI) (36); 24 noninfected
(DTH−/IFAT−) individuals (control group) were also exam-
ined. The criteria used for discriminating between these
clinical-immunological infection profiles were described in
previous studies [2, 5].
2.3. CytokineMeasurements by Flow Cytometry. SerumTNF-
𝛼, IL-4, IL-6, and IL-10 cytokines were detected simultane-
ously in a FACSCanto II flow cytometer using a cytokine
Cytometric Bead Array (CBA) Human enhanced sensitivity
flex set (BD PharMingen), according to the manufacturer’s
instructions. The assays were performed and analyzed by a
single operator using FCAP array software. The detection
range was 274–200,000 fg/mL for each cytokine.
2.4. DataAnalysis. Bio-Estat 5.0 softwarewas used to identify
any statistically significant differences between the serum
cytokine responses of the five clinical-immunological pro-
files. The mean cytokine responses of the five profiles and
the negative control group were compared using the Mann-
Whitney test and, when applicable, the 95% confidence
interval was calculated for descriptive analyses of the data.
The Spearman correlation test was used to analyze cor-
relations between the cytokine responses of each clinical-
immunological profile and the control group. The signifi-
cance level was set at 𝑃 ≤ 0.05.
3. Results
The results of the present work were analyzed by comparing
each cytokine response in terms of the different clinical-
immunological infection profiles and the negative control
group (Mann-Whitney test) and also by comparing each
clinical-immunological infection profile and the negative
control group with the different cytokine responses (Spear-
man correlation). Significantly higher IL-6 serum levels were
found in the SI profile (AVL) in the first analysis as compared
to the other profiles; significantly higher IL-10 serum levels
were also observed in the SI profile (AVL) as compared to
the SOI and the control group (CG) and in the AI and III
profiles as compared to the SOI. Additionally, significantly
higher TNF-𝛼 serum levels were detected in the SI profile
(AVL) as compared to CG and in the AI profile as compared
to the III. No significant differences in IL-4 serum levels
were observed between the different clinical-immunological
infection profiles (AI, SRI, III, SOI, and SI) andCG (Figure 2).
Positive correlations were observed in the second analysis
between IL-6 and IL-10 serum levels in the SI [AVL] (𝑟
𝑠
= 0.8
and 𝑃 ≤ 0.05) and III (𝑟
𝑠
= 0.5 and 𝑃 ≤ 0.05) profiles, as
well as between IL-6 and TNF-𝛼 and between IL-4 and TNF-
𝛼 serum levels in the III (𝑟
𝑠
= 0.4 and 𝑃 ≤ 0.05) profile
(Figure 3).
4. Discussion
This represents the first study carried out in Brazil that
analyzed TNF-𝛼, IL-4, IL-6, and IL-10 serum levels using
flow cytometry along the wide clinical-immunological spec-
trum of human L. (L.) i. chagasi-infection composed of
five different profiles (SI [AVL], SOI, III, SRI, and AI).
Following infection, the antigenic stimuli of the parasite
promotes first-line host defenses through the innate immune
response which functions during the evolution of infection
are sustained by the production of proinflammatory (TNF-
𝛼, IL-1𝛽, IL-6, IL-8, IL-12, and IFN-𝛾) and anti-inflammatory
(TGF-𝛽, IL-4, and IL-10) cytokines. Here, we evaluated the
role of some well-known prominent proinflammatory (TNF-
𝛼 and IL-6) and anti-inflammatory (IL-4 and IL-10) cytokines
within the entire clinical-immunological spectrum of human
L. (L.) i. chagasi-infection to better understand their roles in
the immunopathogenesis of infection.
It has been suggested that TNF-𝛼 is involved in acute
inflammatory responses against Gram-negative bacterial
infections, as well as other infectious agents [18, 19]. Its prin-
cipal function appears to be the stimulation and recruit-
ment of neutrophils and monocytes to infection sites and
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Figure 2: Flow cytometric assays showing the TNF-𝛼, IL-4, IL-6, and IL-10 cytokine concentrations in 161 serum samples of L. (L.) i. chagasi-
infected and noninfected individuals from an endemic area of AVL in the municipality of Barcarena, Para´ State, in the Brazilian Amazon,
representing the following five clinical-immunological profiles of infection: AVL = SI (21 cases), SOI (12), III (49), SRI (19), AI (36), and 24
noninfected (DTH−/IFAT−) individuals (CG). (a) TNF-𝛼: tumor necrosis factor-alpha; (b) IL-6: interleukin-6; (c) IL-4: interleukin-4, and
(d) IL-10: interleukin-10. AVL (American visceral leishmaniasis) = SI (symptomatic Infection profile); SOI (subclinical Oligosymptomatic
Infection profile); III (indeterminate Initial Infection profile); SRI (subclinical Resistant Infection profile); AI (asymptomatic Infection profile);
and CG (control Group).
their activation to kill pathogenic microorganisms. TNF-𝛼
encodes genes that codify TNF-𝛼 and TNF-𝛽 and is asso-
ciated with severe infectious diseases, including malaria,
mucocutaneous leishmaniasis, visceral leishmaniasis, and
tuberculosis; the latter two diseases are associated with high
TNF-𝛼 serum/plasma levels [15–17, 20]. We demonstrated
here significantly higher TNF-𝛼 serum levels in the SI (AVL)
profile than in CG and in the AI profile as compared to
III, demonstrating for the first time in Brazil that during
early onset of infection with a negative DTH response (III
profile) TNF-𝛼 serum levels are lower than those seen in resis-
tant asymptomatic infections with positive DTH responses
(AI profile) or in susceptible symptomatic infections with
negative DTH responses (SI profile [AVL]). Based on these
results, it seems reasonable to assume that, depending on the
genetic profile for the DTH response of infected individual,
the indeterminate initial infection (III profile with negative
DTH) may evolve either with moderate TNF-𝛼 serum levels
in resistant asymptomatic individuals (AI profile with posi-
tive DTH) or with elevated TNF-𝛼 serum levels in susceptible
symptomatic patients (SI profile [AVL] with negative DTH),
suggesting that the innate immune response-derived TNF-
𝛼 protector effect is associated with other cell-mediated
immunitymechanisms, such as delayed-type hypersensitivity
(DTH). It should not be forgotten, however, that previous
studies have shown that DTH and TNF-𝛼 expressions during
the evolution of human L. (L.) i. chagasi-infection are strongly
associated with the genetic profiles of the infected individuals
[4, 17].
In terms of other proinflammatory cytokines, it is well
known that IL-6 is produced by several cell lines, includ-
ing antigen presenting cells (APCs) such as macrophages,
dendritic cells, and B cells; IL-6 is also involved in the
acute phase of inflammatory response, B cell maturation, and
macrophage differentiation [21]. Patients with visceral leish-
maniasis show high IL-6 serum levels during the evolution
BioMed Research International 5
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Figure 3: Positive correlations between the responses of IL-6 and IL-10 in the SI=AVL and III clinical-immunological profiles of human L. (L.)
i. chagasi infection, as well as between IL-6 and TNF-𝛼 and IL-4 and TNF-𝛼 in the III profile from an endemic area of AVL in themunicipality
of Barcarena, Para´ State, in the Brazilian Amazon. TNF-𝛼: tumor necrosis factor-alpha; IL-6: interleukin-6; IL-4: interleukin-4; and IL-10:
interleukin-10. III: indeterminate Initial Infection profile; SI = AVL: symptomatic Infection profile = American visceral leishmaniasis.
of the disease, as this cytokine acts by blocking macrophage
activation, in addition to its microbicidal activity [22, 23]. It
has also been suggested that IL-6 is able to control Th1/Th2
differentiation, promotingTh2 differentiation while simulta-
neously inhibiting Th1 polarization; it activates transcription
mediated by the nuclear factor of activated T cells (NFAT),
leading to the production of IL-4 by naive CD4(+) T-cells and
their differentiation into effector Th2 cells. IL-6 thus inhibits
Th1 differentiation by upregulating suppressor of cytokine
signaling- (SOCS-) 1 expression that will interfere with IFN-𝛾
and the development of Th1 cells [24]. Additionally, IL-6 was
recently identified as the central proinflammatory cytokine
responsible for the lethalmanifestations observed in pediatric
patients that eventually died due to severe AVL in Piaui State,
in northeastern Brazil [11].
As such, the potential pathogenic effects of IL-6 were well
characterized in the present work, not only in terms of its
significantly higher serum levels in the SI profile (AVL) as
compared to the other profiles, but also because of the fact
that it was the only cytokine that produced serum levels in the
SI profile (AVL) that were significantly higher than those seen
in the other profiles, confirming its strong ability to promote
Th2 differentiation to the detriment of Th1 polarization, and
pushing human L. (L.) i. chagasi-infection to the susceptible
immunopathological pole of the spectrum (SI profile [AVL]).
Additionally, it should be noted that even during the early
onset of infection with negative DTH response (III profile)
IL-6 showed significantly higher serum levels than those of
TNF-𝛼, IL-4, and IL-10, suggesting that it exerts a latent
immunopathogenic effect even during early infection onset.
It is therefore interesting to note a recent clinical finding of
significantly higher IL-6 serum levels as compared to TNF-
𝛼, IL-4, and IL-10 in an asymptomatic 3-year-old girl with
negative DTH and positive IFAT (IgG: 640) [III profile] who
went on to develop classical AVL (IgG: 10.240) [SI profile] six
weeks later [25].
With respect to the anti-inflammatory cytokine IL-4,
a possible association between three functional IL-4 poly-
morphisms (−590 C/T (rs2243250), −34 C/T (rs2070874),
and 70 bp VNTR [rs79071878 in intron3]) and kala-azar was
recently described in an Indian cohort comprising 197
patients and 193 healthy controls—but no associations of
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IL-4 functional polymorphisms with the disease were iden-
tified. It was therefore postulated that other vital genes
involved in the IL-4 pathway could provide genetic clues of
IL-4 regulation and immunopathogenesis during kala-azar
[26]. We found here that IL-4 was the anti-inflammatory
cytokine showing the lowest serum levels within the entire
clinical-immunological spectrum of human L. (L.) i. chagasi-
infection, with no significant correlation (𝑃 ≥ 0.05) of its
serum levels with any of the infection profiles (SI [AVL], SOI,
III, SRI, and AI) or the control group (CG), suggesting that
IL-4 has no discriminatory expression during the evolution
of infection, even in regard to the pathogenic SI profile (AVL).
In terms of the other anti-inflammatory cytokines, it is
well known that IL-10 is principally produced by Leishmania-
infectedmacrophages, favoring the intracellular development
of that parasite. Its production by CD4(+) T-cells is also
important for parasite maintenance, even following a clinical
cure of infection, and represents a pivotal key for developing
adaptive immunity against the parasite [27, 28]. It has also
been observed, in vitro, that IL-10 is responsible for the
inhibition of IFN-𝛾 production, but the addition of anti-
IL-10 antibodies to cell cultures converts the IFN-𝛾 pro-
duction and, subsequently, the lymphoproliferative responses
of asymptomatic infected individuals (with positive DTH),
suggesting that high levels of IL-10 are strongly associated
with AVL (SI profile), making it a critical cytokine in the
immunopathogenesis of this disease [12]. Interestingly, these
observations are partially in agreement with the results of
this study, as significantly higher IL-10 serum levels were
seen in the SI profile (AVL) than in SOI or CG and in the
AI and III profiles as compared to SOI, demonstrating, for
the first time within the entire clinical-immunopathological
spectrum of human L. (L.) i. chagasi-infection, that while IL-
10 expression is intensively associated with AVL patients (SI
profile with negative DTH), it is also associated to a lesser
degree with both resistant (AI profile with positive DTH)
and indeterminate individuals (III profile with negative
DTH), indicating its immune-regulator role in those stages of
infection. It is likewise important to emphasize our previous
findings demonstrating similar IL-10 serum levels in both the
AI and III profiles as compared to those in cured AVL (SI
profile) patients (nine cases at least two years after treatment)
[29], confirming the relevant role of this cytokine not only in
the dynamics of the clinical and immunological evolution of
human L. (L.) i. chagasi-infection [6, 7] but also in the process
of AVL recovery.
When our results were examined with basis on each
clinical-immunological profile of infection in relation to the
proinflammatory (TNF-𝛼 and IL-6) and anti-inflammatory
(IL-4 and IL-10) cytokines, at least four positive correlations
were evident, including two between IL-6 and IL-10 in the
SI (AVL) and III profiles (both marked by negative DTH
responses), respectively, clearly suggesting a competition
between IL-6 and IL-10 cytokines in these infection profiles
evolving in the absence of a DTH response; the third was
between IL-6 and TNF-𝛼 as seen in the III profile, which
might be viewed as an attempt of the innate immune
response to ensure a protective response against infection
in indeterminate asymptomatic individuals (III profile). As
such, it is interesting to note that follow-up efforts of 49 III
cases examined in the present study failed to identify a single
individual that progressed to a SI profile (AVL) after one
year. Additionally, taking into account that the SRI and AI
profiles (both marked by positive DTH response) represent
subsequent stages of infection (III profile) among individuals
with resistant genetic background, it is interesting to note
that our results failed to show any difference between IL-
6 and TNF-𝛼 serum levels in either of those two profiles,
reinforcing the possibility that a positive correlation between
these cytokines in the III profile might favors a protective
innate immune response against infection; the fourth was
between the IL-4 and TNF-𝛼 cytokines, also in the III profile,
suggesting, again, competition between anti-inflammatory
(IL-4) and proinflammatory (TNF-𝛼) cytokines in infection
profiles developing in the absence of a DTH response.
5. Conclusion
The results of the present work provide strong evidence
for the association of IL-6 and IL-10 cytokines with the
immunopathogenesis of the extremely pathogenic SI profile
(AVL) and likewise clarify the role of proinflammatory (TNF-
𝛼 and IL-6) and anti-inflammatory (IL-4 and IL-10) cytokines
within the clinical-immunological spectrum of human L. (L.)
i. chagasi-infection.
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